Product Overview

Amaryl 3mg is a prescription antidiabetic medication produced by Sanofi India Limited. Each strip contains 30 tablets, each delivering a strength of 3mg of glimepiride. The product is indicated for the treatment of type 2 diabetes mellitus when diet and exercise alone are insufficient to achieve adequate glycemic control. Pack sizes of 30, 60, and 90 tablets are available, with a typical delivery window of 6 to 15 days.

What is Amaryl 3mg?

Amaryl 3mg belongs to the sulfonylurea class of oral hypoglycemic agents. The active ingredient, glimepiride, works by stimulating pancreatic beta cells to release insulin, thereby lowering blood glucose levels. It is classified as a second‑generation sulfonylurea, offering a longer duration of action and a lower risk of hypoglycemia compared with first‑generation agents. The medication is marketed under the brand name Amaryl and is sourced from a reputable manufacturer with a history of compliance with international quality standards.

Uses and Benefits

Clinicians prescribe Amaryl 3mg to help patients with type 2 diabetes achieve target hemoglobin A1c levels and reduce the risk of diabetes‑related complications. In addition to improving glycemic control, studies suggest that consistent use of glimepiride may contribute to modest improvements in cardiovascular risk factors when combined with lifestyle modifications. The oral route provides convenience for patients who prefer tablet therapy over injectable options, and the once‑daily dosing schedule supports adherence.

How It Works

The mechanism of action of glimepiride involves binding to the sulfonylurea receptor (SUR1) on the surface of pancreatic beta cells. This binding leads to closure of ATP‑sensitive potassium channels, depolarization of the cell membrane, and subsequent influx of calcium ions, which triggers insulin secretion. The released insulin enhances peripheral glucose uptake and suppresses hepatic glucose production, resulting in a net decrease in circulating blood glucose concentrations. Because the drug’s effect is glucose‑dependent, the likelihood of hypoglycemia is lower when used appropriately.

Dosage Guidelines

Initial therapy typically starts with one 3mg tablet taken with breakfast or the first main meal of the day. Dosage may be titrated upward in increments of 1–2mg at intervals of 1–2 weeks, based on patient response and blood glucose monitoring, up to a maximum daily dose of 6mg (two tablets). Patients with renal impairment or those over 65 years of age may require lower starting doses. If a dose is missed, the patient should take it as soon as remembered unless it is near the time of the next scheduled dose; in that case, the missed dose should be skipped and regular dosing resumed.

Side Effects

Like all medications, Amaryl 3mg can cause adverse effects. The most commonly reported side effects include hypoglycemia, dizziness, headache, and mild gastrointestinal discomfort. Less frequent but clinically significant events involve hepatic enzyme elevations, skin reactions such as rash or pruritus, and weight gain. Rarely, severe hypersensitivity reactions or agranulocytosis have been reported. Patients should be instructed to monitor blood glucose regularly and to seek medical attention if symptoms of severe hypoglycemia (e.g., confusion, seizures) occur.

Warnings and Precautions

Amaryl 3mg is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, or a history of hypersensitivity to glimepiride or any component of the formulation. Caution is advised in individuals with moderate to severe renal or hepatic impairment, as well as in those with adrenal or pituitary insufficiency. The medication should be used with care during pregnancy and breastfeeding only when the expected benefit justifies potential risks. Potential drug interactions include non‑steroidal anti‑inflammatory drugs, certain antibiotics, and alcohol, which may potentiate hypoglycemia or alter drug metabolism.

Additional Information

The product is supplied in blister packs containing 30 tablets per strip. Available pack sizes are 30, 60, and 90 tablets, allowing patients to select the quantity that best fits their treatment plan. Storage should be at room temperature, away from moisture and direct sunlight. For regulatory details, refer to the FDA product label (https://www.fda.gov/drugs/drug-approvals-and-databases/drug-label-information) and the National Institutes of Health (NIH) diabetes resources (https://www.ncbi.nlm.nih.gov/books/NBK538695/).

Frequently Asked Questions

What is the recommended starting dose of Amaryl 3mg?

The usual starting dose is one 3mg tablet taken with the first main meal of the day. Dose adjustment is based on blood glucose response and may be increased gradually.

Can Amaryl 3mg be used together with insulin?

Yes, glimepiride can be combined with insulin therapy, but clinicians must monitor for an increased risk of hypoglycemia and adjust doses accordingly.

How long does it take to see a reduction in HbA1c levels?

Clinical studies show that a noticeable decrease in HbA1c can be observed within 4–6 weeks of consistent therapy, with maximal effect typically reached after 12 weeks.

Is Amaryl 3mg safe for elderly patients?

Elderly patients may be more sensitive to hypoglycemia; a lower initial dose and careful titration are recommended.

Where can I find the full prescribing information?

Complete prescribing details are available on the FDA label page (https://www.fda.gov/drugs/drug-approvals-and-databases/drug-label-information) and on Drugs.com (https://www.drugs.com/monograph/glimepiride.html).